GDP for B Cell Lymphomas – pro
Diffuse large B-cell lymphomas (DLBCLs) are quite often curable with intensive combination chemotherapy. Despite the improvement of outcome with chemoimmunotherapy, 30-40% of patients relapse after the first-line treatment, and the rate of the second complete remission is lower than 30%.
The GDP regimen was initially studied as salvage regimen for Hodgkin’s lymphoma and then for salvage of B Cell large cell Lymphoma, with the addition of rituximab. It is well accepted in the situation of this patient and NCCN lists it on p. BCEL-C, 2.
Hou Y, Wang H, Ba Y. Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed or aggressive B-cell lymphoma. Med Oncol. 2012;29:2409–2416.
Gopal A, Press O, Pagel J. Efficacy and Safety of Gemcitabine (G), Carboplatin ©, Dexamethasone (D), and Rituximab in Patients with Relapsed/Refractory Lymphoma: A Prospective Multi-center Phase II Study of by the Puget Sound Oncology Consortium (PSOC). Leuk Lymphoma. 2010;51:1523–1529.
NCCN. B Cell Lymphomas, 2016